New drug combo targets Tough-to-Treat myeloma

NCT ID NCT07648459

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativity) and improve outcomes like response rate and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CM336 (anti-BCMA/CD3 bispecific antibody)
What this could lead to: If successful, this could offer a more effective treatment option for people with high-risk multiple myeloma, potentially leading to longer periods without cancer progression.
What could go wrong: This is an early-phase trial with only 46 participants, so results may not apply to everyone. The drug may cause side effects, and it is not a cure—patients will still need ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.